Medica has reached an agreement with IK Partners on the terms of a recommended all-cash offer at 212p per share. The acquisition values Medica at £269m (fully diluted), a 32.5% premium to the closing price prior to the announcement. The offer is recommended by Medica’s board. At the time of the announcement, IK Partners has received irrevocable undertakings for c.20% of Medica’s share register. If approved, the deal is expected to become effective in Q2 2023.
Medica’s prelims are in line with our expectations. Encouragingly 2023 has started well supported by new contract wins across the board and a recovery in Elective activity, and our expectations for the full year are unchanged. Good progress continues to be made increasing reporter capacity and Medica has completed two small and inexpensive bolt-on acquisitions post-period end to further strengthen this. We remain of the view that the current multiple of just under 10x FY23 EV/EBITDA looks undema...
A director at Medica Group bought 59,900 shares at 125p and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
Medica is the UK leader in teleradiology. Teleradiology is the electronic transmission and remote assessment of radiological images, including CT, MRI and x-ray scans. Hospitals transmit these images through Medica's platform to a network of remote radiologists who, from their own home, review and
Medica Group is the UK market leader in teleradiology — the transmission, interpretation and reporting of radiological images, such as X-rays, magnetic resonance imaging (MRI) and computerised tomography (CT) scans, remotely from where the patient is imaged. This market has been growing strongly ac
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.